Fig. 7: Combination of 8a and gemcitabine inhibits pancreatic cancer growth in vivo. | Cell Death & Disease

Fig. 7: Combination of 8a and gemcitabine inhibits pancreatic cancer growth in vivo.

From: Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine

Fig. 7: Combination of 8a and gemcitabine inhibits pancreatic cancer growth in vivo.

a–c Mice bearing BXPC-3 xenografts were treated with vehicle control, 8a (20 mg/kg), gemcitabine (10 mg/kg), or their combination. Tumor growth curve (a), tumor weight (b), and visible tumor formation (c) were shown. d Body weight changes of mice during treatment. e–g Ki67 and cleaved-Caspase 3 were analyzed in tumor tissues at the end of experiments by immunohistochemical staining (scale bar: 100 μm). h–k Representative western blots of Ac-H3K9, H3, pro-Caspase 3, cleaved-Caspase 3, Ki67, SIRT6 and β-Actin levels in three representative BXPC-3 xenograft tumors from each group in vivo. Data presented as mean ± SD of six mice per group. **P < 0.01, ***P < 0.001, versus control. ##P < 0.01, ###P < 0.001, versus GEM group.

Back to article page